C-Type Natriuretic Peptide (CNP) (1-22), human

C-Type Natriuretic Peptide (CNP) (1-22), human

• CAS Number: 127869-51-6
• UNSPSC Description: C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].
• Target Antigen: Histamine Receptor
• Type: Peptides
• Related Pathways: GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Metabolic Disease; Neurological Disease; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/C-Type_Natriuretic_Peptide__CNP___1-22_,_human.html
• Purity: 99.41
• Solubility: H2O : 50 mg/mL (adjust pH to 3 with 0.5%CH3COOH)
• Smiles: O=C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CC2=CC=CC=C2)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NC1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN
• Molecular Weight: 2197.60
• References & Citations: [1]Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.|[2]Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680.|[3]Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported